Understanding genetic risk factors for type 2 diabetes
Phenotyping Children and Adults With Possible High or Low Genetic Risk for Type 2 Diabetes
This study is trying to see how genetic risk for type 2 diabetes affects blood sugar control and insulin response in people who don't have diabetes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 10 Years to 70 Years |
| Sex | All |
| Sponsor | University of Pennsylvania Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Philadelphia, Pennsylvania and 1 other locations) |
| Trial ID | NCT04024631 on ClinicalTrials.gov |
What this trial studies
This study investigates how genetic risk scores for type 2 diabetes affect glucose tolerance and insulin resistance in non-diabetic individuals. Participants will be recruited from biobank populations and will undergo a four-hour oral glucose tolerance test and a whole body DXA scan. The study aims to compare individuals with high genetic risk scores to those with low scores to better understand the implications of genetic predisposition on metabolic health.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 10-70 years with a BMI of 25kg/m2 or higher, who have previously participated in the UPenn Biobank.
Not a fit: Patients with a prior diagnosis of type 1 or type 2 diabetes or those on medications affecting glucose metabolism will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved screening and prevention strategies for individuals at high genetic risk for type 2 diabetes.
How similar studies have performed: Other studies have shown success in using genetic risk scores to predict diabetes risk, making this approach both relevant and promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 10-70 years * Prior participant of the UPenn Biobank or Center for Applied Genomics Biobank and agreed to be recontacted for future research. * Adults with BMI 25kg/m2 or higher, children and adolescents with BMI 85th percentile or higher Exclusion Criteria: * prior diagnosis of type 1, type 2, or secondary diabetes * use of medications that would impact glucose and insulin response such as steroids, metformin or other anti-diabetic medication * acute illness that may impact insulin and glucose dynamics * pregnancy * hypothalamic obesity or related genetic disorder of metabolism * recent systemic chemotherapy use * gastrointestinal impairment or surgery that may impact absorption * anemia * major organ system illness or any underlying condition requiring regular medication or treatment that could make implementation of the protocol or interpretation of the study results difficult * inability to comply with study protocol
Where this trial is running
Philadelphia, Pennsylvania and 1 other locations
- Childrens Hospital of Philadelphia — Philadelphia, Pennsylvania, United States (Not_yet_recruiting)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Jessica R Wilson, MD, MS — University of Pennsylvania
- Study coordinator: Jessica R Wilson, MD, MS
- Email: jessica.wilson3@uphs.upenn.edu
- Phone: 215 898-3389
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.